In This Article:
The United States market has shown robust performance with a 4.5% rise over the last week and an 11% increase in the past year, supported by an anticipated annual earnings growth of 14%. In this favorable environment, identifying high growth tech stocks that align with these positive trends can be key to capitalizing on potential opportunities.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 26.28% | 37.43% | ★★★★★★ |
Ardelyx | 20.57% | 59.97% | ★★★★★★ |
Travere Therapeutics | 25.75% | 64.53% | ★★★★★★ |
Blueprint Medicines | 21.36% | 61.45% | ★★★★★★ |
TG Therapeutics | 25.99% | 38.42% | ★★★★★★ |
Alnylam Pharmaceuticals | 23.65% | 61.11% | ★★★★★★ |
AVITA Medical | 27.28% | 60.66% | ★★★★★★ |
Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
Lumentum Holdings | 21.59% | 110.32% | ★★★★★★ |
Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Alnylam Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★★
Overview: Alnylam Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics utilizing ribonucleic acid interference technology and has a market capitalization of approximately $34.89 billion.
Operations: Alnylam Pharmaceuticals generates revenue primarily from the discovery, development, and commercialization of RNAi therapeutics, amounting to $2.35 billion. The company leverages ribonucleic acid interference technology as a core component of its business model.
Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is demonstrating significant strides in its sector with a projected annual revenue growth of 23.7% and earnings growth forecast at 61.1%. The company's commitment to innovation is underscored by its R&D expenses which are substantial, reflecting its focus on developing treatments for conditions like ATTR amyloidosis with cardiomyopathy. Recent approvals of AMVUTTRA® for ATTR-CM in the U.S. and Brazil highlight their progress and potential market impact. Moreover, Alnylam's recent presentation at the Heart Failure 2025 Congress further solidifies its position as a pioneer in addressing rare diseases through advanced RNAi therapies, promising enhanced patient outcomes with fewer doses per year.
Netflix
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Netflix, Inc. is a leading provider of entertainment services with a market capitalization of approximately $489.83 billion.